| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T84 |
0-94 |
Sentence |
denotes |
On March 16, 2020, Moderna, through a partnership with the Vaccine Research Center at the U.S. |
| T85 |
95-656 |
Sentence |
denotes |
National Institutes of Health, enrolled the first participants into a Phase I clinical trial testing an mRNA vaccine (mRNA-1273) encapsulated in lipid NPs—a record time of just 63 days following sequence selection (NCT04283461).65 The enrollment of the first cohort of participants (18 to 55-year-old healthy subjects) concluded on April 16, 2020.66 CureVac and BioNTech (in partnership with Pfizer) are currently working on similar vaccines; Pfizer/BioNTech, in particular, have recently started the recruitment in Phase I/II trials (NCT04368728, NCT04380701). |
| T86 |
657-894 |
Sentence |
denotes |
A DNA plasmid vaccine by Inovio Pharmaceuticals (INO-4800) has showed promising results in mice and guinea pigs according to a recent article published in Nature Communications(67) and has entered Phase I testing in humans (NCT04336410). |
